Administering IgE antagonists during pregnancy to ameliorate allergic diseases in the offspring
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 17, 2002
app pub date -
Jan 12, 2001
filing date -
Jan 14, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to IgE antagonists, including monoclonal antibodies, and their use in ameliorating asthma and allergic diseases in offspring of mothers treated during pregnancy with such antagonists. The preferred IgE antagonists do not induce release of the mediators of allergy. One example of such IgE antagonists are anti-IgE antibodies which bind to secreted IgE, to membrane IgE on the surface of IgE-producing B cells, but not to IgE bound to the Fc.di-elect cons.RI on the surface of basophils or mast cells. Preferably, these antibodies also do not bind to IgE bound to Fc.di-elect cons.RII receptors. It is also preferable if these antibodies have human IgG1 or IgG3 constant regions, as well as further human portions, if desired.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully